Penserra Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Penserra Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,275	Closed	-$21K	–	1561
2021 Q3	$21K	Buy	1,275 +10	+0.8%	+$175	﹤0.01%	1241
2021 Q2	$27K	Buy	1,265 +20	+2%	+$358	﹤0.01%	1108
2021 Q1	$18K	Sell	1,245 -10	-0.8%	-$162	﹤0.01%	983
2020 Q4	$16K	Buy	1,255 +789	+169%	+$9.5K	﹤0.01%	880
2020 Q3	$4K	Buy	+466	New	+$4.98K	﹤0.01%	871

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Penserra Capital Management's VNDA Position: Q4 2021 in Review

Penserra Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2021, closing a stake of 1,275 shares — an estimated $21K sold.

Penserra Capital Management first reported a position in VNDA in Q3 2020 and held it in 5 quarters. The position peaked at $27K in Q2 2021. 198 funds tracked by Wall St. Rank hold VNDA as of Q4 2021.

Penserra Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 1,275 Vanda Pharmaceuticals shares in Q4 2021, an estimated $21K.
Penserra Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Penserra Capital Management's Vanda Pharmaceuticals position peaked at $27K in Q2 2021.
198 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.